8-K: Citius Oncology Launches LYMPHIR for CTCL Treatment

Citius Oncology, a subsidiary of Citius Pharmaceuticals, announced the commercial launch of LYMPHIR for relapsed or refractory Stage I-III cutaneous T-cell lymphoma in the U.S.

Summary

• Citius Oncology, a majority-owned subsidiary of Citius Pharmaceuticals, commercially launched LYMPHIR (denileukin diftitox-cxdl) in the U.S. on December 1, 2025.
• LYMPHIR is approved by the U.S. Food and Drug Administration (FDA) for adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.
• The estimated addressable U.S. market for LYMPHIR is over $400 million and is projected to grow.
• Citius Pharmaceuticals' other pipeline assets, Mino-Lok and Halo-Lido, have completed trials with positive results.
• Mino-Lok's Phase 3 trial met primary and secondary endpoints, demonstrating superiority in extending time to catheter failure (median time to failure: control arm 33 days vs. Mino-Lok arm exceeding 6 weeks, p-value = 0.0006).
• Halo-Lido's Phase 2b trial showed a meaningful reduction in hemorrhoidal symptom severity when compared to individual components alone.

Sentiment

Score: 8

Explanation: The commercial launch of LYMPHIR, an FDA-approved product for a significant market, combined with positive Phase 3 data for Mino-Lok and positive Phase 2b data for Halo-Lido, represents strong progress across the company's pipeline. While there are significant safety warnings for LYMPHIR and ongoing funding needs, the overall news is highly positive for the company's commercial and developmental trajectory.

Positives

• Commercial launch of LYMPHIR, the first new systemic CTCL therapy since 2018, addressing a clear clinical need in a disease with limited treatment options.
• Estimated addressable U.S. market for LYMPHIR is over $400 million with strong growth opportunities and potential for international market access and expanded indications.
• LYMPHIR demonstrated an Objective Response Rate (ORR) of 36.2% in pivotal trials, with 84% of evaluable patients experiencing a reduction in skin tumor burden and a median time to response of 1.4 months.
• LYMPHIR was not associated with cumulative toxicity, offering a powerful new approach to disease control.
• Mino-Lok Phase 3 trial achieved primary and secondary endpoints with positive topline data, showing significant outperformance against control in extending time to catheter failure (p-value = 0.0006).
• Mino-Lok was well-tolerated with no drug-related serious adverse events.
• Halo-Lido Phase 2b trial showed positive results with a meaningful reduction in hemorrhoidal symptom severity.
• LYMPHIR has a 12-year BLA exclusivity and robust intellectual property protections, including orphan drug designation and pending patents for immuno-oncology use.
• LYMPHIR has been included in the National Comprehensive Cancer Network (NCCN) Guidelines for CTCL with a Category 2A recommendation.

Negatives

• CTCL is considered incurable, and current treatments are non-curative, often having a limited duration of response and/or being discontinued early.
• LYMPHIR carries a Boxed Warning for Capillary Leak Syndrome (CLS), including life-threatening or fatal reactions, which occurred in 27% of patients in pooled clinical trials (8% Grade 3, 0.8% fatal).
• Other serious adverse reactions for LYMPHIR include visual impairment (9%), infusion-related reactions (69%), and hepatotoxicity (elevated ALT in 70% of patients, AST in 64%).
• LYMPHIR can cause fetal harm when administered to a pregnant woman and may compromise male fertility.

Risks

• Need for substantial additional funds and the ability to raise additional money to fund operations for at least the next 12 months as a going concern.
• Ability to successfully commercialize LYMPHIR, including covering the costs of licensing payments, product manufacturing, and other third-party goods and services.
• Ability to obtain, perform under, and maintain financing and strategic agreements and relationships.
• Ability to maintain compliance with Nasdaq's continued listing requirements.
• Risks relating to the results of research and development activities, including those from existing and any new pipeline assets.
• Dependence on third-party suppliers and the ability to procure cGMP commercial-scale supply.
• Uncertainties relating to preclinical and clinical testing.
• Patent and intellectual property matters.
• Government regulation and competition.
• Capillary Leak Syndrome (CLS), including life-threatening or fatal reactions, can occur in patients receiving LYMPHIR.
• LYMPHIR can cause serious visual impairment, infusion-related reactions, and hepatotoxicity.
• LYMPHIR can cause fetal harm when administered to a pregnant woman and may compromise male fertility.
• Physician and patient acceptance of LYMPHIR in a competitive treatment landscape.
• Reliance on third-party logistics providers, distributors, and specialty pharmacies to support commercial operations.
• Ability to educate providers and payers, secure adequate reimbursement, and maintain uninterrupted product supply.
• Post-marketing requirements and ongoing regulatory compliance related to LYMPHIR.

Future Outlook

Citius Oncology expects LYMPHIR to be a meaningful addition to the CTCL treatment paradigm and a value-driving catalyst, with further upside opportunities through international market access and potential expanded indications. The company is pursuing label expansion for LYMPHIR in combination with KEYTRUDA for recurrent or metastatic solid tumors and with CAR T therapies for high-risk relapsed/refractory B-cell lymphomas, with preliminary data anticipated in Q1 2026. Citius Pharmaceuticals anticipates monetizing Halo-Lido with a strategic or financial partner and is in active discussions for additional international distribution partners for LYMPHIR.

Management Comments

• "LYMPHIR is an important new treatment option for the CTCL community, and its launch marks the beginning of a new chapter for Citius Oncology. With a median time to response of 1.4 months in the Phase 3 trial, we believe LYMPHIR may offer rapid skin relief, among other benefits, to patients suffering from severe and debilitating itching common with the disease." Leonard Mazur, Chairman and CEO of Citius Oncology and Citius Pharmaceuticals.
• "This is our first marketed product and the culmination of years of development work and commercial preparation. LYMPHIR addresses a clear clinical need in a disease with limited treatment options. Ultimately, we expect LYMPHIR to be a meaningful addition to the treatment paradigm for CTCL and a value-driving catalyst for Citius Oncology shareholders." Leonard Mazur.
• "We estimate that LYMPHIR is entering a growing U.S. market valued at over $400 million, with further upside opportunities through international market access and potential expanded indications in the future. Our focus now is on execution to ensure that LYMPHIR reaches the patients who need it." Leonard Mazur.
• "LYMPHIR is an important new tool in the fight against CTCL. It is the only FDA-approved systemic therapy for CTCL in more than seven years." Dr. Myron Czuczman, Executive Vice President and Chief Medical Officer of Citius Oncology and Citius Pharma.
• "LYMPHIRs direct tumoricidal activity and transient T-regulatory cell depletion offer a powerful new approach to disease control without cumulative toxicity. As such, LYMPHIRs clinical profile makes it a compelling treatment option for physicians and patients facing the burden of relapsed or refractory CTCL." Dr. Myron Czuczman.

Industry Context

The CTCL market is characterized as an orphan cancer with severe quality-of-life impact and limited systemic treatment options. LYMPHIR is the first new FDA-approved systemic CTCL therapy in over seven years, entering a market where patients often cycle through multiple non-curative therapies. Its differentiated mechanism of action, targeting the IL-2 receptor for direct tumoricidal activity and T-regulatory cell depletion, positions it as a novel option in a landscape of treatments with various limitations, aiming to improve patient outcomes and quality of life.

Comparison to Industry Standards

• LYMPHIR is the only FDA-approved systemic therapy for CTCL in more than seven years, filling a significant gap in treatment options.
• Unlike some existing CTCL therapies, LYMPHIR does not require a CD30+ biomarker, allowing for broader applicability.
• LYMPHIR has a broad label and is not associated with cumulative toxicity, which is a limitation for other treatments like Romidepsin (cumulative bone marrow toxicity) or those causing peripheral neuropathy.
• LYMPHIR offers rapid skin relief (median time to response of 1.4 months), addressing severe pruritus, a significant quality-of-life issue for CTCL patients, which may differentiate it from therapies that primarily act on blood disease rather than skin manifestations.
• Compared to treatments like Mogamulizumab (requires CD30+ biomarker, peripheral neuropathy risk) or Brentuximab Vedotin (most effective in SS subtype, acts on blood disease), LYMPHIR's clinical profile and MOA aim to provide a compelling alternative where current therapies are limited.

Stakeholder Impact

• Shareholders: Potential for increased revenue and value creation from the LYMPHIR launch and pipeline progress, though also a risk of dilution from future capital raises.
• Patients (CTCL): Access to a new FDA-approved systemic therapy (LYMPHIR) with a differentiated mechanism of action, offering rapid skin relief and no cumulative toxicity, addressing an unmet need.
• Patients (CLABSI): Potential for a novel treatment (Mino-Lok) to salvage infected catheters, reducing complications, discomfort, and costs associated with catheter removal and replacement.
• Patients (Hemorrhoids): Potential for the first FDA-approved prescription product (Halo-Lido) to treat hemorrhoids.
• Healthcare Providers: New treatment option (LYMPHIR) for CTCL, supported by comprehensive educational and reimbursement resources.

Next Steps

• Execution to ensure LYMPHIR reaches the patients who need it across the U.S.
• Further evaluation of LYMPHIR in combination with KEYTRUDA across a broader range of solid tumor types, with preliminary data anticipated in Q1 2026.
• Further evaluation of LYMPHIR in combination with CAR T therapies for high-risk relapsed/refractory B-cell lymphomas, with preliminary study results anticipated in Q1 2026.
• Ongoing FDA engagement regarding next steps for both Mino-Lok and Halo-Lido programs.
• Monetizing the value of Halo-Lido with a strategic or financial partner.
• Active discussions with multiple additional prospective distribution partners for LYMPHIR across several European Union member states, in South America, and in select Middle Eastern territories.

Key Dates

Recommendation

The commercial launch of LYMPHIR, an FDA-approved product targeting a $400M+ market, is a significant milestone that should drive revenue growth. The positive Phase 3 data for Mino-Lok, addressing a multi-billion dollar market with no approved salvage therapy, and positive Phase 2b data for Halo-Lido further de-risk the pipeline. While there are safety warnings for LYMPHIR and a stated need for future funding, the company's progress across multiple late-stage assets, combined with a clear path to market for LYMPHIR, presents a compelling investment opportunity. The company's shared management services agreement for Citius Oncology also suggests capital efficiency.

Keywords

Citius Pharmaceuticals, Citius Oncology, LYMPHIR, CTCL, Cutaneous T-cell Lymphoma, Mino-Lok, CLABSI, Catheter-Related Bloodstream Infection, Halo-Lido, Hemorrhoids, FDA approval, Commercial launch, Biopharmaceutical, Oncology, Rare disease, Orphan drug